Addiction recovery is one of the most important things health insurance can help pay for — and fortunately, the ACA provides stronger protections for substance use disorder treatment than almost any other category of care. But knowing what is covered, how to access it, and what the realistic limits are can make the difference between getting into treatment and getting stuck in a coverage battle. This guide explains what ACA plans must cover on the Gulf Coast, what they are never required to cover (including sober living housing), and how to navigate the authorization process.
Substance use disorder (SUD) treatment is one of the ten essential health benefits established by the Affordable Care Act. Every ACA marketplace plan sold on the Gulf Coast — in Florida, Texas, Alabama, Mississippi, and Louisiana — must cover substance use disorder services. This is not optional for plans, and it applies at all metal tiers from Bronze through Platinum.
Additionally, the Mental Health Parity and Addiction Equity Act (MHPAEA) requires that SUD benefits be provided on par with medical and surgical benefits. This means an insurer cannot impose a strict 30-day limit on residential rehab coverage if it does not apply comparable limits to medical inpatient stays. It cannot require prior authorization for SUD care while providing easier access to comparable medical care. Parity violations are actionable — if you believe your plan is treating your SUD claim more restrictively than a medical claim, you have grounds for an appeal.
ACA marketplace plans cover the full continuum of evidence-based addiction treatment, subject to prior authorization requirements and network availability:
Medication-Assisted Treatment (MAT) combines FDA-approved medications with counseling and behavioral therapies to treat substance use disorders. It is the most evidence-based approach to opioid use disorder and is also used for alcohol use disorder. MAT is an ACA essential benefit, and ACA plans must cover it.
For opioid use disorder, the primary MAT medications are:
For alcohol use disorder, FDA-approved medications include naltrexone (oral and injectable), acamprosate (Campral), and disulfiram (Antabuse). All are covered under ACA pharmacy benefits, though formulary placement and prior authorization requirements vary by plan.
One of the most important things to understand about addiction coverage is what it does not include: sober living houses. Sober living homes — also called recovery residences, Oxford Houses, or halfway houses — are peer-supported, substance-free living environments that provide structure and community for people in recovery. They are not licensed medical treatment facilities and do not provide clinical services.
Because sober living is housing, not healthcare, it is not a health insurance benefit. The monthly rent at a sober living home — typically $600–$1,800 per month on the Gulf Coast — is entirely the resident's responsibility. Some residents use income-based scholarships offered by nonprofit operators; others work with state-funded recovery support services. But health insurance will not pay for sober living, regardless of clinical need or recommendation.
The practical implication: treatment ends when the clinical program ends, not when the person feels fully stable in recovery. After completing an IOP, a person transitions to standard outpatient and community support (like 12-step programs or SMART Recovery), not to an insurance-covered sober house stay. Helping a family member plan financially for sober living costs is as important as understanding the insurance coverage for the treatment program itself.
Residential addiction treatment almost always requires prior authorization. The standard approach used by behavioral health insurers is the American Society of Addiction Medicine (ASAM) Criteria — a widely accepted framework for determining the appropriate level of care based on six assessment dimensions including intoxication and withdrawal potential, medical conditions, emotional and behavioral conditions, readiness to change, relapse potential, and recovery environment.
To obtain prior authorization for residential treatment, your insurer will typically need: the treating clinician's assessment documenting ASAM level-of-care criteria; the diagnosis (specific substance use disorder); the proposed facility's name, license, and accreditation; and clinical documentation supporting why lower levels of care are not sufficient. Many treatment facilities have dedicated utilization review staff who handle this process — use them.
Length of stay limitations are a major battleground. Insurers often authorize short stays (7–14 days) and then review for continued medical necessity. If the clinical team believes a longer stay is necessary and the insurer disagrees, the appeals process described below applies.
Not all addiction treatment facilities accept insurance, and not all that do are in-network with your specific plan. Out-of-network residential treatment can result in balance bills far exceeding what insurance covers. Before admission to a non-emergency program, verify network status by calling your insurer's behavioral health line and asking whether the specific facility is in-network.
The SAMHSA Behavioral Health Treatment Services Locator at findtreatment.gov is a federally maintained directory of substance use disorder treatment facilities. You can filter by type of care, payment accepted, and location. Your plan's behavioral health line can also provide a list of in-network residential programs in your area.
The SAMHSA National Helpline — 1-800-662-4357 — is a free, confidential, 24/7 referral service that connects individuals and families to local treatment programs, support groups, and community resources. It does not require insurance and is a good starting point when navigating options in a crisis situation.
Coverage denials for addiction treatment are common, but many are reversed on appeal. If your insurer denies authorization for residential treatment or continues to deny coverage for ongoing care, take these steps:
Florida has a history of patient brokering concerns in its large addiction treatment industry — be cautious of facilities offering to pay for transportation or other inducements to choose their program, and verify CARF or JCAHO accreditation when selecting a residential program.
Gulf Coast states have experienced above-average opioid overdose death rates, with fentanyl driving the majority of overdose fatalities in recent years. MAT remains substantially underutilized relative to clinical need, particularly in rural areas of Mississippi, Alabama, and coastal Louisiana where OTPs and buprenorphine-prescribing providers are less accessible. ACA marketplace coverage for MAT exists in all Gulf Coast states, and patients eligible for subsidized coverage through the marketplace can access these benefits at low or no cost after premium tax credits. If you or a family member is struggling with opioid use disorder, accessing treatment through an ACA plan is one of the most impactful uses of that coverage.